Skip to content
10-Q

Quarterly Report

PLIANT THERAPEUTICS, INC. PLRX

0001746473-25-000099

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 61.39M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $30.28M
Long Term Debt Q1 2025 · Dec 31, 2024 $30.21M
Short Term Investments Q1 2025 · Mar 31, 2025 $213.71M
Short Term Investments Q1 2025 · Dec 31, 2024 $284.54M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $91.94M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $71.19M
Current Liabilities Q1 2025 · Mar 31, 2025 $28.2M
Current Liabilities Q1 2025 · Dec 31, 2024 $33.22M
Total Liabilities Q1 2025 · Mar 31, 2025 $87.61M
Total Liabilities Q1 2025 · Dec 31, 2024 $92.87M
Current Assets Q1 2025 · Mar 31, 2025 $311.19M
Current Assets Q1 2025 · Dec 31, 2024 $362.26M
Total Assets Q1 2025 · Mar 31, 2025 $344.77M
Total Assets Q1 2025 · Dec 31, 2024 $396.95M
Shares Diluted Q1 2025 · Mar 31, 2024 60.18M sh
Capex Q1 2025 · Mar 31, 2024 $1.49M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$30.27M
Stockholders Equity Q1 2025 · Mar 31, 2024 $437.33M
Stockholders Equity Q1 2025 · Dec 31, 2023 $473.58M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.78
Eps Basic Q1 2025 · Mar 31, 2024 −$0.78
Sga Expense Q1 2025 · Mar 31, 2024 $15.25M
Rd Expense Q1 2025 · Mar 31, 2024 $37.15M
Net Income Q1 2025 · Mar 31, 2024 −$46.96M
Operating Income Q1 2025 · Mar 31, 2024 −$52.39M